Published in Drug Week, December 16th, 2005
The primary end point of the study was the incidence of total (major plus minor) bleeding events seen in patients taking AZD6140 or clopidogrel, which overall was 10.2% for the AZD6140 90 mg twice daily (BID) group, 10.2% for the AZD6140 180 mg BID group, and 9.2% for the clopidogrel 75 mg once daily (QD) group. Within these figures,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week